Tag: Compugen (CGEN)

Compugen Has Encouraging News

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen (CGEN) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with Bristol Myers Squibb’s  (

Compugen: A Stock To Keep

Compugen Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’s technological capability has also enabled it to create therapeutic inhibitors of its two discovered targets. The discoveries happened to be important in improving cancer immunotherapy. The lead therapeutic candidate, COM701 . . . This content is for paid subscribers. Please …

Compugen: Predictive Computational Discovery Technology

Compugen IND Application for Triple Combination Study Cleared by the US FDA The U.S. Food and Drug Administration has cleared Compugen’s (CGEN) investigational new drug (IND) application for its Phase 1/2 study evaluating the triple combination of COM701, Compugen’s first-in-class anti-PVRIG antibody, OPDIVO® (nivolumab) -- Bristol Myers . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Compugen: A New Important Patent from Europe and Much More

Compugen: In the NEWS Compugen (CGEN) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office (EPO). The EPO Patent No. 3295951 titled, “Anti-PVRIG Antibodies and Methods of Use”, covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies …
Compugen: A Small Firm with Giant Technological Capabilities

Compugen: A Small Firm with Giant Technological Capabilities

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting Compugen (CGEN) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG for the treatment of advanced solid tumors, in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I …

Market Frustration, Volatility and Chaos

Stock Market Fluctuations and Volatility  Only history can remind us that what’s going on recently with the stock market is not new. Similar situations have taken place during the terms of every president since Ronald Reagan. Indeed, the same stock market's unexpected tumbling occurred during Reagan, Bush the father, Clinton, Bush the son, Obama and now Trump. As a matter of fact, history reminds us …
The Small Stock That Refused to Kneel in Today’s Market

The Small Stock That Refused to Kneel in Today’s Market

Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen (CGEN). This firm announced good news; we wish it has chosen a better day for its announcement. Compugen's stock managed to rally as investor's enthusiasm was unlimited; knowing, in fact, what the success of Compugen immuno . . . This content is for …
Regeneron and Moderna Are Both Outperforming Today

Regeneron and Moderna Are Both Outperforming Today

Regeneron, Moderna, and COVID-19 The spread of COVID-19, minute creatures that seem to be trying to defeat us, has been accused of bringing the market down over 1000 points yesterday. Investors who love the biotech stocks they carefully and accurately hand-picked should take advantage of the temporary market drop to buy more of their preferred stocks at bargain prices. In so doing, the cost of …
Prohost Letter #439

Prohost Letter #439

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN
A Synopsis of Some Biotech Companies’ Events

A Synopsis of Some Biotech Companies’ Events

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen (AMGN): The stock gained over $10 yesterday and is trading now at $231. Many bloggers continue to attack the firm, mourning the loss of their protective patents on its over 30 years’ old products and ignore the record . . . …
In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A rebounding is expected following an unwarranted decline.   Gilead Sciences (GILD): A lot of good news from the firm, including the firm’s investigational product remdesivir that demonstrated positive results in beating the coronavirus infection. Read yesterday's article posted

Compugen

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen
Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm Therapeutics (KPTI) financial results report revenues from a strong launch of its first approved product. Indeed, the firm’s third-quarter 2019 financial results are the first quarter in which Karyopharm generated revenues. In early July the U.S. FDA granted the company’s product Xpovio® (selinexor . . . This content is for …
The FDA Approves Compugen’s IND for Its Oncology Product COM902

The FDA Approves Compugen’s IND for Its Oncology Product COM902

Compugen FDA Approval for COM902 Compugen Announces FDA Clearance of IND Application for COM902 Phase 1 clinical study in patients with advanced malignancies expected to begin in early 2020 Clinical development of COM902 will enable testing the combination treatment with COM701, Compugen’s anti-PVRIG inhibitor  Compugen (CGEN) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel …
This Past Week

This Past Week

The Week in Review #43 This Past Week After hearing hints about the trade war between China and the United States being avoided the market reversed course from faltering to flying at the speed of light. This trade war replaced all important factors that would usually affect the market performances. Unemployment is the lowest since 1969 and is expected to cause a bullish market, but …
During the Departed Week

During the Departed Week

The Week in Review #42 During the Departed Week The week started with the market losing over 1000 points and ended recuperating a large extent of the losses. Desperate during the market’s plummeting, some investors were happy for the rebound and some were confused and skeptical about what the unpredictable market might bring next. In the latest Prohost Letter #436, the losses in prices of …
The Value of the Biotech Companies Continued

The Value of the Biotech Companies Continued

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A Recap The biotech near and long-term values, we insist, must be based on the firms’ scientific capabilities, products’ potentials and financial results. In the past months the stocks evaluations by bloggers, and some assessors, have been tailored to mislead investors into serving the purposes of the manipulators’ weird agendas. …